GlassScriptPhysician profile
Jessica Bean
NPI 1861876856
$7,470.04
in general payments reported to CMS, 2019-2025
38 companies · $1,494 in 2025
The $1,494 reported for 2025 was more than what 92% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,481 · 2022: $1,123 · 2023: $1,767 · 2024: $1,605 · 2025: $1,494.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,866.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,866.41 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,433.35 | 2021-2025 | Ozempic, Rybelsus, Wegovy |
| Astrazeneca Pharmaceuticals LP | $902.27 | 2021-2025 | Farxiga, Airsupra, Breztri |
| Abbvie INC. | $809.50 | 2021-2025 | |
| Lilly USA, LLC | $468.27 | 2021-2025 | Mounjaro, Jardiance, Emgality |
| Bayer Healthcare Pharmaceuticals INC. | $453.33 | 2021-2025 | |
| Glaxosmithkline, LLC. | $403.35 | 2021-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Amgen INC. | $373.50 | 2021-2025 | Otezla, Repatha, Otezla |
| Pfizer INC. | $288.39 | 2023-2025 | |
| Sumitomo Pharma America, INC. | $247.63 | 2023-2025 | Gemtesa |
| Sanofi-Aventis U.S. LLC | $225.15 | 2021-2023 | |
| Astellas Pharma US INC | $175.48 | 2021-2025 | Veozah, Myrbetriq |
| Abbott Laboratories | $167.64 | 2023-2025 | Freestyle Libre 3 |
| Janssen Pharmaceuticals, INC | $144.45 | 2021-2022 | |
| Organogenesis INC. | $141.35 | 2023 | Puraply |
| Boehringer Ingelheim Pharmaceuticals, INC. | $128.73 | 2021-2025 | Jardiance |
Show all 38 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jessica Bean listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.